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Hepatitis C Infection in two urban hemodialysis units. We determined
the prevalence of antibodies to the hepatitis C virus (anti-HCV) in 90
patients and 37 staff members of two hemodialysis units utilizing a
recently developed anti-HCV recombinant based assay. Eleven pa-
tients (12%) were anti-HCV (+). Of these, eight (73%) had antibodies to
the hepatitis B core antigen (anti-HBc) indicating prior hepatitis B
infection; one patient was hepatitis B surface antigen (HBsAg) (+). All
staff members were anti-HCV (—), although seven (19%) of them were
anti-HBc (+). Alanine aminotransferase elevations were present at the
time of the study in four anti-HCV (—) patients and in only one
anti-HCV (+) patient. All anti-HCV (+) (mean 59 74; range 3 to 269
units) and 85% of anti-HCV (—) patients (mean 16 27; range 0 to 204
units) had received multiple blood transfusions (P = 0.348). Among 50
patients tested for human immunodeficiency virus (HIV), 43% of
anti-HCV (+) as compared to only 7% anti-HCV (—) were positive (P
= 0.003). There was a history of intravenous drug abuse (IVDA) in eight(72%) of the anti-HCV (+) patients and in only seven (9%) of the
anti-HCV (—) group (P = 0.00001). The results of this serologic survey
suggests that anti-HCV positivity is prevalent, although much less than
anti-HBc, among our dialysis patients, whereas it was not detected
among staff members. The prevalence rate of anti-HCV was statistically
significantly higher among anti-HIV (+) and IVDA patients but not in
multi-transfused patients.
Sporadic outbreaks of hepatitis in dialysis units continue to
occur in spite of effective control and prevention of hepatitis B
(HBV) infection [1—5]. These outbreaks are presumably medi-
ated by non-A, non-B (NANB) viruses. The diagnosis of
NANB hepatitis is one of exclusion of other viruses for which
serologic parameters are available, that is, HBV, hepatitis A
(HAY), cytoniegalovirus (CMV), and Epstein Barr virus
(EBV). The recent introduction of an assay for hepatitis C
antibodies (anti-HCV) [6] prompted an investigation of the
prevalence of this infection in our two dialysis units.
Methods
Patients
Study subjects were all the patients (N = 90) undergoing
maintenance hemodialysis and 37 staff members at the Miami
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Veterans Administration (VAMC) and University of Miami!
Jackson Memorial (UM/JMMC) Medical Centers during March
and April of 1989. Routine hemodialysis techniques were used
with four-hour treatments performed thrice weekly, using cu-
prophane dialyzers with acetate or bicarbonate solutions of
standard composition.
In both hospitals, hepatitis B surface antigen (HBsAg)-
positive patients were isolated in a separate room. At the
VAMC, patients with unexplained increases in alanine ami-
notransferase (ALT) also undergo hemodialysis with a separate
machine. Artificial kidneys are not reused. Disinfection of the
dialysis machines includes bleach between patients, heat at the
end of the day and formaldehyde treatment during weekends.
HBsAg, hepatitis B surface antibody (anti-HBs) and hepatitis B
core antibody (anti-HBc) and ALT levels are measured monthly
in anti-HBs seronegative patients. Otherwise, tests are per-
formed every three months. Standard precautions for hepatitis
B infection have been implemented since 1977 [71.
The mean age of the patients was 54 13 (range 25 to 87)
years. There were 68 men and 22 women. Sixty-one patients
were black. Mean duration of maintenance dialysis was 31 36
months (range from 1 month to 15 years). The most common
causes of renal failure were hypertension and nephrosclerosis
(N = 32), diabetic nephropathy (N = 30) and glonierulonephri-
tis (N = 7). Other diagnoses were multiple myeloma, obstruc-
tive nephropathy, human immunodeficiency virus (HIV)-asso-
ciated nephropathy and polycystic kidney disease. Transfusion
records revealed that 87% of the patients received transfusions
(mean 22 38; range 0 to 269 units). Fifteen (17%) patients had
a history of intravenous drug abuse (IVDA).
Of the 37 staff members screened, twenty-five agreed to
complete a questionnaire designed to obtain epidemiological
data. There were 28 women and 9 men. Their mean age was 42
9 years, and they had worked an average of 12.5 years (range
1.2 to 35) in the medical environment and 7.9 years (range 0.2 to
18) in dialysis units. Two of the staff members had a history of
blood transfusion, none admitted IVDA. One staff member had
a history of hepatitis B infection and 21 gave a history of
accidental needlestick or splattering with blood. Ten of 25 had
received hepatitis B vaccination.
Sera from study subjects were obtained during March and
April 1989. Anti-HCV was measured by the method of Kuo et
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Table 1. Prevalence and association of antibodies to HCV and HBc
in two urban hemodialysis units
Anti-HBc
Total no.+ —
Anti-HCV positive 8 3 11(12%)
Anti-HCV negative 33 46 79 (88%)
Total 41(46%) 49 (54%)
Odds ratio = 3.72
Chi-square = 3.73 P = 0.053
Fisher's exact test P = 0.103
a! [6]. In this assay, a polypeptide synthesized in recombinant
yeast cloned of HCV is used to capture circulating viral
antibodies. This test has been shown to have high sensitivity
and 100% specificity. Antibody to the human immunodeficiency
virus (anti-HIV) and hepatitis B markers (HBsAg, anti-HBc,
anti-HBs) were measured with commercially available kits:
HIV-I, Auszyme, Corzyme and Ausab (Abbott Laboratories,
North Chicago, Illinois, USA), respectively. Seroreactive sam-
ples for anti-HIV were confirmed by Western Blot. ALT was
determined with standard automated analyzer techniques. Both
the laboratory technicians and evaluators of the results were
blinded. Statistical analyses for two-way tables were performed
using the Fisher's Exact Probability test. Continuous variables
were analyzed using the Student t-test.
Results
Eleven patients (12%) were positive for anti-HCV. Among
the anti-HCV (+) patients, eight (73%) were positive for anti-
HBc, one of whom was also HBsAg (+) and five of whom were
also anti-HBs (+). Among the 79 anti-HCV (—) patients, 33
(42%) were anti-HBc (+), one of whom was also HBsAg (+)
and 27 of whom were also anti-HBs (+). An analysis was made
to determine whether the presence of anti-HCV and anti-HBc
were related to each other (Table 1). The odds ratio for the data
on Table 1 was 3.72, indicating the tendency for a higher
prevalence of anti-HCV among anti-HBc positive subjects.
However, this did not reach statistical significance according to
the criteria of the study (P = 0.053).
Risk factors in the eleven anti-HCV (+) patients (Table 2)
included blood transfusions (all patients) and IVDA (8 patients).
Nevertheless, 67 (85%) of anti-HCV (—) patients had a history
of blood transfusions and 7 (10%) had a history of IVDA (P =
0.348 and P = 0.00001, odds ratio 27.4, respectively). The
number of transfusion units [anti-HCV (+) 59 77; HCV (—) 16
27] was significantly higher in the anti-HCV (+) patients,
however. (P = 0.004) Fifty patients consented to be tested for
anti-HIV. Three of seven (43%) patients seropositive for anti-
HCV and 3 of 43 (7%) patients seronegative for anti-HCV tested
positive for anti-HIV (P = 0.003, odds ratio 10.0).
Eight (10%) anti-HCV (—) patients and only two (18%)
anti-HCV (+) had prior sporadic increases in ALT levels. One
of the anti-HCV (+) patients had chronic persistent hepatitis
documented by liver biopsy and the other had a history of
chronic alcoholism, abnormal liver function tests, and stigmata
of cirrhosis. At the time of the study, ALT was increased above
normal levels in five patients [4 anti-HCV (—), 1 anti-HCV (+)]
(P = 0.85). The etiology of the increased ALT elevations was
not established. The rest of the patients had no clinical or

















1 34 M B 3 89 — 104 + PR2 28 M H 51 37 + 10 + PRC
3 44 M B 15 26 + 12 + PRC
4 36 M H 6 23 + 23 + —
5 52 M W 36 15 — 28 — —
6 36 M H 24 50 + 45 — +
7 50 M B 38 27 — 33 + PRC
8 44 M B 52 5 + 18 + —
9 34 M B 24 3 + 14 + +
10 44 M B 36 108 + 26 — —
11 44 M B 120 269 + 29 + +
Abbreviations are: HD, hemodialysis; Tx, transfusion units; IVDA,
intravenous drug abuse; ALT, alanine aminotransferase (normal values
7 to 56 U/liter).
a HBsAg (+)b B, Black; W, White; H, Hispanic
C PR, Patient refused test
laboratory evidence of chronic liver disease; liver biopsies were
not performed, however.
Of the 37 staff members, none were anti-HCV (+) and seven
(19%) were anti-HBc (+)/antiHBs (+). The prevalence of
anti-HBc was significantly lower than that of the patients (P =
0.001). They were not tested for anti-HIV. ALT levels were
normal in all staff members.
Discussion
Hepatitis continues to be a serious problem in chronic
dialysis units even after the introduction of serological tests and
vaccines for HBV infection and universal precaution standards
[1—5]. The available data suggests that HCV is a major cause of
NANB hepatitis throughout the world [61. In our dialysis
patients, 46% of whom were anti-HBc (+), we obtained a
prevalence rate of anti-HCV of 12%. Two recent surveys from
Spain and Germany in groups at risk for parenterally transmit-
ted forms of viral hepatitis disclosed prevalence rates of HCV
of 20 and 5.5%, respectively [8, 9].
The personnel had a mean exposure period of 7.5 years in a
dialysis setting and 19% had evidence of previous exposure to
HBV infection. However, none had serologic evidence of HCV
infection, suggesting that HCV is not as readily transmitted as
HBV in this environment.
The main risk factors for HCV infection in our patients were
intravenous drug abuse and, to a lesser degree, blood transfu-
sions. Nevertheless, 84% of anti-HCV (—) patients also had
received blood transfusions, and there were seven IVDA
among them. The mean number of transfusions in the seven
IVDA that were anti-HCV (—) was lower than that in the eight
IVDA that were anti-HCV (+) (9 units vs. 65 units). In the
study from Spain, the incidence of anti-HCV in patients at risk
was IVDA 70%, post-transfusion NANB hepatitis 80% [8]. It
may be surprising that we found such a low prevalence of HCV
infection in our patients. A substantial percentage of anti-HCV
(—) patients were anti-HBc (+) suggesting that they had been
previously infected with HBV. It is conceivable that uremic
patients are unable to mount or sustain significant antibody
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titers. Alternatively, this new test may be unable to detect low
levels of anti-HCV and this may result in a falsely low preva-
lence of anti-HCV.
Anti-HBc, a marker of HBV infection, has recently been
recognized as a surrogate marker for NANB hepatitis [10].
Although of borderline statistical significance, this association
was suggested by the results of the present study in that eight of
the 11 anti-HCV (+) patients were positive for anti-HBc.
Sporadic prior increases or current elevations of ALT, how-
ever, did not correlate with anti-HCV positivity. Three of our
anti-HCV (+) patients had prior or current increases in ALT,
but one of them had stigmata of chronic liver disease and a
history of excessive alcohol consumption. Conversely, 12 anti-
HCV (—) patients had unexplained increases in ALT. In a
recently published study, surrogate assays for anti-HBc would
have detected only half of the anti-HCV (+) donors involved in
the transmission of hepatitis [11].
The elimination of anti-HCV (+) from the blood donor pool
together with institution of improved infection control measures
for the anti-HCV (+) dialysis patients should further reduce the
incidence of dialysis associated hepatitis. Since the advent of
strict prophylaxis for HBV and HIV, there is a decrease
likelihood for nosocomial transmission of HCV infection [12].
Nevertheless, further studies are necessary to evaluate the
infectivity of anti-HCV (+) patients and the potential for cross
infection in the dialysis setting.
Acknowledgments
We thank Ana Ortiz for manuscript preparation.
Reprint requests to Lennox J. Jeffers, M.D., F.A.C.P., Center for
Liver Diseases, University of Miami School of Medicine, P.O. Box
016960 (R-10), Miami, Florida 33101, USA.
I. MARCHES! D, ARId C, POLETTI E, MINGARDI G, MINOLA E,
MECCA 0: Outbreak of non-A, non-B hepatitis in center hemodial-
ysis patients: A retrospective analysis. Nephrol Dial Transplant
3:795—799, 1988
2. SHUSTERMAN N, SINGER I: Infectious hepatitis in dialysis patients.
Am J Kid Dis 9:447—455, 1987
3. PARFREY PS, FARGE D, FORBES RD. DANDAvINO R, KENICK S,
GUTTMAN RD: Chronic hepatitis in end-stage renal disease: Com-
parison of HBsAg-negative and HBsAg-positive patients. Kidney
mt 28:959—967, 1985
4. KORETZ RL, STONE 0, MousA M, GITNICK 0: The pursuit of
hepatitis in dialysis units. Am J Nephrol 4:222—226, 1984
5. POLAKOFF S: Hepatitis in dialysis units in the United Kingdom: A
Public Health Laboratory Service Survey. J Hyg (Lond) 87:443.-
451, 1981
6. Kuo G, CHoo QL, ALTER HJ, et al: An assay for circulating
antibodies to a major etiologic virus of human non-A, non-B
hepatitis. Science 244:362—364, 1989
7. Centers for Disease Control: Control measures for hepatitis B in
dialysis centers, in Hepatitis Surveillance Report No. 41, Atlanta,
Centers for Disease Control, 1977, pp. 1—12
8. ESTEBAN JI, VILADOMIU L, GONZALEZ A, et a!: Hepatitis C virus
antibodies among risk groups in Spain. Lancet ii:294—296, 1989
9. ROGGENDORF M, DEINHARDT F, RASSHOFER R, et al: Antibody to
hepatitis C virus in German blood donors. Lancet ii:324—325, 1989
10. Li KN, TAM JS, LAI FM, LIN Hi: Isolated presence of antibody
to hepatitis B core antigen in dialysis patients: occurrence of
subclinical hepatitis? Am J Kid Dis 13:370—376, 1989
11. ALTER Hi, PURCELL RH, SHIN JW: Detection of antibody to
hepatitis virus in prospectively followed transfusion recipients with
acute and chronic non-A, non-B hepatitis. N Engi J Med 321:1494—
1500, 1989
12. FAVEROMS: Recommended precautions for patients undergoing
hemodialysis who have AIDS or non-A, non-B hepatitis. Infect
Control 6:304—305, 1985
References
